## Abstract ## Background. The purpose of this article is to report the overall survival (OS) outcome of patients with nasopharyngeal carcinoma (NPC) with local failure who received salvage treatment and to identify prognostic factors for OS. ## Methods. Between January 1996 and December 2000, 2
Lung metastasis alone in nasopharyngeal carcinoma: A relatively favorable prognostic group : A study by the Hong Kong Nasopharyngeal Carcinoma Study Group
β Scribed by Edwin P. Hui; Sing F. Leung; Joseph S. K. Au; Benny Zee; Stewart Tung; Daniel Chua; Wai M. Sze; Chun K. Law; To W. Leung; Anthony T. C. Chan
- Publisher
- John Wiley and Sons
- Year
- 2004
- Tongue
- English
- Weight
- 195 KB
- Volume
- 101
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BACKGROUND
The current study was conducted to examine the pattern and the predictive factors of distant metastases (DM) in patients with nasopharyngeal carcinoma (NPC) after primary radiotherapy treatment.
METHODS
Data from all five regional cancer centers in Hong Kong were collected retrospectively and pooled for the current study, which was coordinated by the Hong Kong Nasopharyngeal Carcinoma Study Group. The sample was comprised of all 2915 patients with NPC without DM at the time of presentation who were treated with radiotherapy in 1 of the 5 cancer centers during the period between January 1996 and December 2000.
RESULTS
DM was found to be the leading cause of NPC failure, with a 5βyear actuarial rate of 14.9% in this patient cohort. Despite the poor overall survival (OS) of these patients, those with lung metastasis alone represented a distinctive group associated with a significantly better OS. International Union Against Cancer (UICC) N classification, UICC T classification, advanced age, and male gender were found to be significant and independent determinants for DM.
CONCLUSIONS
Longβterm survival is possible in patients with distant metastatic NPC confined to the lung. An aggressive approach to treatment for this group of patients should be considered. Cancer 2004. Β© 2004 American Cancer Society.
π SIMILAR VOLUMES
chemotherapy in patients with
## Abstract ## BACKGROUND The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapyβnaΓ―ve, advancedβstage nonβsmall cell lung carcinoma (NSCLC). ## METHODS